Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
20 April 2022 - 11:05PM
via NewMediaWire -- Neovasc, Inc. (Neovasc or the
Company) ( NASDAQ , TSX : NVCN) today announced
that its management team will be participating in the 2022 Bloom
Burton & Co. Healthcare Investment Conference to be held May
2-3, 2022. Fred Colen, Neovasc’s Chief Executive Officer, will be
presenting at 4:00 pm ET on Monday, May 2.
The presentation can be accessed here.
Additionally, a recording of the presentation will be available on
the conference website, and will be archived for 90 days.
About Neovasc Inc.
Neovasc is a specialty medical device company that
develops, manufactures, and markets products for the rapidly
growing cardiovascular marketplace. Its products include Reducer,
for the treatment of refractory angina, which is under clinical
investigation in the United States and has been commercially
available in Europe since 2015, and Tiara™ for the transcatheter
treatment of mitral valve disease, which is currently under
clinical investigation in the United States, Canada, Israel and
Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words expect, anticipate, estimate, may, will, should,
intend, believe, and similar expressions, are intended to identify
forward-looking statements. Forward-looking statements may involve,
but are not limited to, the Company’s participation at the Bloom
Burton & Co. Healthcare Investment Conference and the timing
thereof and the growing cardiovascular marketplace. Forward-looking
statements are based on estimates and assumptions made by the
Company in light of its experience and its perception of historical
trends, current conditions and expected future developments, as
well as other factors that the Company believes are appropriate in
the circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the Risk Factors section of the
Company’s Annual Report on Form 20-F and in the Managements
Discussion and Analysis for the year ended December 31, 2021
(copies of which may be obtained
at www.sedar.com or www.sec.gov ). These
factors should be considered carefully, and readers should not
place undue reliance on the Company’s forward-looking statements.
The Company has no intention and undertakes no obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contacts
InvestorsMike CavanaughWestwicke/ICRPhone:
+1.617.877.9641Mike.Cavanaugh@westwicke.com
Media
Sean LeousWestwicke/ICRPhone:
+1.646.866.4012Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024